Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.
about
An agenda for research on adverse drug reactionsStrong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patientsHigh-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity.New advances in DPYD genotype and risk of severe toxicity under capecitabine.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsAbsence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.Personalized treatment for patients with colorectal cancer: role of biomarkers.A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics.Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study.Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics.Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution ExperienceFrequent intragenic rearrangements of DPYD in colorectal tumours
P2860
Q28469318-BD685034-053F-4D8D-B696-BEFE111D4509Q28474358-C17FC43A-DC25-4969-A0B9-4D5328DD3FE9Q33405398-3823556C-1D33-4FC9-9A92-E311EEDDA472Q33648195-6E556BD9-D015-4131-9231-4BF0668AD8E4Q34008793-13DB557F-5345-4865-8C25-20FEDF47E6C8Q34026282-382DE5A2-43D6-4995-BBE5-9CD087C28B17Q34216563-9F85E85F-3139-4F2A-B54D-79E8C5A67D4BQ36709301-06276079-CED5-45A4-A109-46C86C1D9B18Q36976499-F4DC05F0-160F-4238-A159-B8F25DDCB582Q38121743-C8F78566-D3AC-4EEE-B70D-F2847E1A89B1Q38390834-F6FA0BFD-DFC9-4E09-8837-9EF4E1F3683BQ42388782-6AB00A2E-4F19-4409-BA54-88D2317EA215Q43212481-B173887C-512E-4FD5-BF36-64FF023092A8Q44716275-E18D6450-C0FF-4E0E-8A99-F0026A4BAAC8Q45967307-8FC92B46-C2A0-4A68-867C-DBD352E22FC5Q47597667-036A192B-78CD-4E69-9A55-296519A2A5FCQ57054536-1C217F15-BA11-4FEA-AD2D-349BE4BF308DQ58407923-D86B003B-CCA6-48BE-9ABE-22CD2DCFE659
P2860
Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Dihydropyrimidine dehydrogenas ...... veloping 5FU-related toxicity.
@ast
Dihydropyrimidine dehydrogenas ...... veloping 5FU-related toxicity.
@en
type
label
Dihydropyrimidine dehydrogenas ...... veloping 5FU-related toxicity.
@ast
Dihydropyrimidine dehydrogenas ...... veloping 5FU-related toxicity.
@en
prefLabel
Dihydropyrimidine dehydrogenas ...... veloping 5FU-related toxicity.
@ast
Dihydropyrimidine dehydrogenas ...... veloping 5FU-related toxicity.
@en
P2093
P2860
P1476
Dihydropyrimidine dehydrogenas ...... veloping 5FU-related toxicity.
@en
P2093
Gérard Milano
Jean-Louis Formento
Laurent Cals
Marie-Christine Etienne-Grimaldi
Mireille Francoual
Nicolas Magné
Nicole Renée
P2860
P304
P356
10.1111/J.1365-2125.2007.02869.X
P407
P577
2007-03-01T00:00:00Z